Pyxis Oncology Inc
NASDAQ:PYXS
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1.51
6.59
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Pyxis Oncology Inc
Pyxis Oncology Inc
Revenue
Pyxis Oncology Inc
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Pyxis Oncology Inc
NASDAQ:PYXS
|
Revenue
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$55.5B
|
CAGR 3-Years
0%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$28.3B
|
CAGR 3-Years
1%
|
CAGR 5-Years
5%
|
CAGR 10-Years
3%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$32.5B
|
CAGR 3-Years
8%
|
CAGR 5-Years
7%
|
CAGR 10-Years
5%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$10.6B
|
CAGR 3-Years
14%
|
CAGR 5-Years
24%
|
CAGR 10-Years
30%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.8B
|
CAGR 3-Years
1%
|
CAGR 5-Years
16%
|
CAGR 10-Years
18%
|
|
Pyxis Oncology Inc
Glance View
Pyxis Oncology, Inc. engages in the development of antibody therapeutics. The company is headquartered in Cambridge, Massachusetts and currently employs 56 full-time employees. The company went IPO on 2021-10-08. The firm has developed a portfolio of antibody drug conjugate (ADC), immuno-oncology (IO), product candidates, and monoclonal antibody (mAb), preclinical discovery programs that are developing as monotherapies and in combination with other therapies. Its pipeline includes PYX-106, PYX-102, PYX-201, PYX-202 and PYX-203. Its PYX-106 is an investigational, fully human IgG1 isotype Siglec-15 targeting antibody that is designed to block Siglec-15-mediated suppression of T-cell proliferation and function. PYX-102 is an investigational immune-therapeutic consisting of a ligand-blocking antibody which rescues KLRG1-mediated suppression of human CD8+ T cells. PYX-201 is an investigational ADC consisting of an immunoglobulin G1 (IgG1), anti-fibronectin Extradomain-B (EDB), mAb site-specifically conjugated to auristatin via a cathepsin B-cleavable linker.
See Also
What is Pyxis Oncology Inc's Revenue?
Revenue
0
USD
Based on the financial report for Dec 31, 2023, Pyxis Oncology Inc's Revenue amounts to 0 USD.
You don't have any saved screeners yet
